In vitro test ‘could prevent another Northwick Park‘

- Last updated on GMT

Related tags: White blood cells, Pharmacology

Simple preclinical experiments should be able to predict whether immunotherapeutic medicines are safe to advance to preclinical testing in humans and avoid the Northwick Park trial that left six healthy volunteers hospitalised.

Researchers from the UK’s National Institute for Biological Standards and Control (NIBSC) have developed the test, which effectively reproduces the devastating immunological reaction suffered by the Northwick Park volunteers in isolated human cells.

Dr Stephen Poole, speaking at the British Pharmacological Society's Winter Meeting in Brighton, said: “we are still investigating why the effect of this drug was so catastrophically different in the clinic than in preclinical testing​.”

[But] we have at least managed to develop new preclinical tests that should help us to avoid such outcomes in the future​."

The Northwick Park trial in 2006 involved an immunotherapeutic called TGN1412, developed by German biotech company Tegenero, which was administered to patients at a clinical facility operated by contract research organisation (CRO) Parexel.

Standard preclinical in vitro​ tests on TGN1412 failed to predict the catastrophic reaction that occurred when the drug was administered to human subjects.

The disaster resulted in the UK Medicine and Healthcare products Regulatory Agency (MHRA) suspending all clinical trials of immunotherapy drugs and commissioning NIBSC, a government-funded institute, to investigate why preclinical tests had failed to predict the response to the drug.

The new measures laid out by the NISBC include ensuring that such drugs are not tested solely on white blood cells in isolation. The NIBSC group has shown that having a mixed human cell culture of white blood cells and endothelial cells – the cells that line blood vessels – is a much better indicator of how this type of drug will react in vivo​.

The NIBSC group has also developed a technique that dries the drug onto a plastic surface, rather than testing it on cells as a solution in water, which has proven to be a far more reliable indicator of how the drug will react in the human body.

Related news

Show more

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Related suppliers

Follow us


View more